Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 9, 2004, Pages 731-743

  Dubinsky, Marla C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 MMP; 6 MP; 6 TGN; 6 thio GTP; 6 thioguanine nucleotides; 6 thioguanine triphosphate; AZA; azathioprine; CI; confidence interval; IBD; inflammatory bowel disease; thioinosine monophosphate; TiMP; TPMT

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NUCLEOTIDE; OLSALAZINE; PREDNISONE; PRODRUG; STEROID; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL PAIN; APOPTOSIS; BIOTRANSFORMATION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONGENITAL MALFORMATION; CORRELATION ANALYSIS; CROHN DISEASE; CYTOTOXICITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; FETUS WASTAGE; FEVER; FLU LIKE SYNDROME; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEPATITIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER TOXICITY; LOW BIRTH WEIGHT; LYMPHOCYTE; MAINTENANCE THERAPY; MALAISE; MALIGNANT NEOPLASTIC DISEASE; METABOLITE; NAUSEA; PANCREATITIS; PATIENT; PERINATAL MORTALITY; PREGNANCY; PROTEIN FUNCTION; RECURRENT DISEASE; REMISSION; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT INDICATION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREGNANCY;

EID: 4444224484     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00344-1     Document Type: Review

References (80)

1. E.C. Van Os, B.J. Zins, W.J. Sandborn, D.C. Mays, W.J. Tremaine, D.W. Mahoney, A.R. Zinsmeister, J.J. Lipsky Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration Gut 39 1996 63 68
2. T.L. Ding, L.Z. Benet Comparative bioavailability and pharmacokinetic study of azathioprine and 6-mercaptopurine in the rhesus monkey Drug Metab Dispos 7 1979 373 377
3. I. Tiede, G. Fritz, S. Strand, D. Poppe, R. Dvorsky, D. Strand, H.A. Lehr, S. Wirtz, C. Becker, R. Atreya, J. Mudter, K. Hildner, B. Bartsch, M. Holtmann, R. Blumberg, H. Walczak, H. Iven, P.R. Galle, M.R. Ahmadian, M.F. Neurath CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 2003 1133 1145
4. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 339
5. R.M. Weinshilboum, S.L. Sladek Mercaptopurine pharmacogenetics monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am J Hum Genet 32 1980 651 662
6. Y.Y. Hon, M.Y. Fessing, C.H. Pui, M.V. Relling, E.Y. Krynetski, W.E. Evans Polymorphism of the thiopurine S-methyltransferase gene in African-Americans Hum Mol Genet 8 1999 371 376
7. F.J. Lee, W. Kalow Thiopurine S methyltransferase activity in a Chinese population Clin Pharmacol Ther 54 1993 28 33
8. H.L. Tai, E.Y. Krynetski, C.R. Yates, T. Loennechen, M.Y. Fessing, N.F. Krynetskaia, W.E. Evans Thiopurine S-methyltransferase deficiency two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians Am J Hum Genet 58 1996 694 702
9. D.M. Otterness, C.L. Szumlanski, T.C. Wood, R.M. Weinshilboum Human thiopurine methyltransferase pharmacogenetics kindred with a terminal exon splice junction mutation that results in loss of activity J Clin Invest 101 1998 1036 1044
10. L. Lennard, J.A. Van Loon, R.M. Weinshilboum Pharmacogenetics of acute azathioprine toxicity relationship to thiopurine methyltransferase genetic polymorphism Clin Pharmacol Ther 46 1989 149 154
11. M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, Y. Theoret, E.G. Seidman Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
12. L. Lennard, J.S. Lilleyman Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia J Clin Oncol 7 1989 1816 1823
13. L. Lennard, J.A. Van Loon, R.M. Weinshilboum Pharmacogenetics of acute azathioprine toxicity purine methyltransferase genetic polymorphism Clin Pharmacol Ther 46 1989 149 154
14. C.L. Szumlanski, R.M. Weinshilboum Sulphasalazine inhibition of thiopurine methyltransferase possible mechanism for interaction with 6-mercaptopurine and azathioprine Br J Clin Pharmacol 39 1995 456 459
15. L.D. Lewis, A. Benin, C.L. Szumlanski, D.M. Otterness, L. Lennard, R.M. Weinshilboum, D.W. Nierenberg Olsalazine and 6-mercaptopurine-related bone marrow suppression a possible drug-drug interaction Clin Pharmacol Ther 62 1997 464 475
16. P.W. Lowry, C.L. Franklin, A.L. Weaver, C.L. Szumlanski, D.C. Mays, E.V. Loftus, W.J. Tremaine, J.J. Lipsky, R.M. Weinshilboum, W.J. Sandborn Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide Gut 49 2001 656 664
17. O. Dewitt, R. Vanheuverzwyn, J.P. Desager, Y. Horsmans Interaction between azathioprine and aminosalicylates an in vivo study in patients with Crohn's disease Aliment Pharmacol Ther 16 2002 79 85
18. D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar, B.S. Pasternack Treatment of Crohn's disease with 6-mercaptopurine a long-term, randomized, double blind study N Engl J Med 302 1980 981 987
19. J. Rhodes, D. Bainton, P. Beck, H. Campbell Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 1273 1276
20. J.M.T. Willoughby, P.J. Kumar, J. Beckett, A.M. Dawson Controlled trial of azathioprine in Crohn's disease Lancet 731 1971 944 947
21. R.W. Summers, D.M. Switz, J.T. Sessions Jr, J.M. Becktel, W.R. Best, F. Kern Jr, J.W. Singleton National Cooperative Crohn's Disease Study results of drug treatment Gastroenterology 77 1979 847 869
22. S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, R. Goodman A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
23. K. Ewe, A.G. Press, C.C. Singe, M. Stufler, B. Ueberschaer, G. Hommel, K.H. Meyer zum Buschenfelde Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 105 1993 367 372
24. M. Klein, H.J. Binder, M. Mitchell, R. Aaronson, H. Spiro Treatment of Crohn's disease with azathioprine a controlled evaluation Gastroenterology 66 1974 916 922
25. D.C. Pearson, G.R. May, G.H. Fick, L.R. Sutherland Azathioprine and 6-mercaptopurine in Crohn's disease a meta-analysis Ann Intern Med 123 1995 132 142
26. Sandborn W., Sutherland L., Pearson D., May G., Modigliani R., Prantera C. Azathioprine or 6-mercaptopurine or inducing remission of Crohn's disease Cochrane Database Syst Rev 3 2000
27. P. Munkholm, E. Langholz, M. Davidsen, V. Binder Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 35 1994 360 362
28. J. Markowitz, K. Grancher, N. Kohn, M. Lesser, F. Daum A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease Gastroenterology 119 2000 895 902
29. J.L. Rosenberg, B. Levin, A.J. Wall, J.B. Kirsner A controlled trial of azathioprine in the management of Crohn's disease Dig Dis 20 1975 721 726
30. Pearson D.C., May G.R., Fick G., Sutherland L.R. Azathioprine for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 3 2003
31. D.P. O'Donoghue, A.M. Dawson, J. Powell-Tuck Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease Lancet 2 1978 955 957
32. T. Lecomte, J.F. Contou, L. Beaugerie, F. Carbonnel, S. Cattan, J.P. Gendre, J. Cosnes Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine Dis Colon Rectum 46 2003 1469 1475
33. B. Korelitz, S. Hanauer, P. Rutgeerts, D. Present, M. Peppercorn Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease a 2 year multicenter trial Gastroenterology 114 1998 A1011
34. X. Roblin, F. Serre-Debeauvais, J.M. Phelip, G. Besssard, B. Bonaz Drug interaction between infliximab and azathioprine in patients with Crohn's disease Aliment Pharmacol Ther 18 2003 917 925
35. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, A. Carbonez, P. Rutgeerts Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608
36. R.J. Farrell, M. Alsahli, Y.T. Jeen, K.R. Falchuk, M.A. Peppercorn, P. Michetti Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease a randomized controlled trial Gastroenterology 124 2003 917 924
37. D.P. Jewell, S.C. Truelove Azathioprine in ulcerative colitis final report on controlled therapeutic trial BMJ 4 1974 627 630
38. A.P. Kirk, J.E. Lennard-Jones Controlled trial of azathioprine in chronic ulcerative colitis BMJ 284 1982 1291 1292
39. A.B. Hawthorne, R.F. Logan, C.J. Hawkey, P.N. Foster, A.T. Axon, E.T. Swarbrick, B.B. Scott, J.E. Lennard-Jones Randomized controlled trial of azathioprine withdrawal in ulcerative colitis BMJ 305 1992 20 22
40. J.L. Rosenberg, A.J. Wall, B. Levin, H.J. Binder, J.B. Kirsner A controlled trial of azathioprine in the management of ulcerative colitis Gastroenterology 69 1975 96 99
41. R.D. Cohen, R. Stein, S.B. Hanauer Intravenous cyclosporine in ulcerative colitis a five-year experience Am J Gastroenterol 94 1999 1587 1592
42. Y. Bouhnik, M. Lemann, J.Y. Mary, G. Scemama, R. Tai, C. Matuchansky, R. Modigliani, J.C. Rambaud Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine Lancet 347 1996 215 219
43. M. Lemann, Y. Bouhnik, J.F. Colombel, B. Duclos, J.C. Soule, E. Lerebours, J.Y. Mary, R. Modigliani Randomized, double blind placebo controlled multicenter, azathioprine withdrawal trial in Crohn's disease Gastroenterology 122 2002 A23
44. G. D'Haens, K. Geboes, P. Rutgeerts Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine Gastrointest Endosc 50 1999 667 671
45. G.J. Mantzaris, K. Petraki, H.C. Iordanides, A. Christidou, A. Karagiannidis, J. Glarakis, E. Archavlis, G. Triantafyllou Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease Gastroenterology 122 2002 A81
46. D.P. McGovern, S.P. Travis, J. Duley, M. Shobowale-Bakre, H.R. Dalton Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity Gastroenterology 122 2002 838 889
47. M.C. Dubinsky, E.A. Vasiliauskas, H. Singh, M.T. Abreu, K.A. Papadakis, T. Tran, P. Martin, J.M. Vierling, S.A. Geller, S.R. Targan, F.F. Poordad 6-thioguanine (6-TG) can cause serious liver injury in inflammatory bowel disease (IBD) patients Gastroenterology 125 2003 298 303
48. B.S. Kirschner Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease Gastroenterology 115 1998 813 821
49. W.R. Connell, M.A. Kamm, J.K. Ritchie, J.E. Lennard Jones Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience Gut 34 1993 1081 1085
50. D.H. Present, S.J. Meltzer, M.P. Krumholz, A. Wolke, B.I. Korelitz 6-Mercaptopurine in the management of inflammatory bowel disease short- and long-term toxicity Ann Intern Med 111 1989 641 649
51. J.F. Colombel, E.J. Loftus, W.J. Tremaine, L.J. Egan, W.S. Harmsen, C.D. Schleck, A.R. Zinsmeister, W.J. Sandborn The safety profile of infliximab for Crohn's disease in clinical practice the Mayo Clinical experience in 500 patients Gastroenterology 126 2004 19 31
52. M.C. Dubinsky, P.V. Hassard, E.G. Seidman, L.Y. Kam, M.T. Abreu, S.R. Targan, E.A. Vasiliauskas Preliminary evidence suggests that 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease Gastroenterology 122 2002 904 915
53. L.C. Stork, E.H. Broxson, H. Sather, P. Gaynon, Y.H. Matloub, R. Yanosfsky, A. Sorrell, L. Wells, M. Masterson, R.J. Hutchinson, M. Blake, R.J. Sokol Oral 6-thioguanine causes late onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia Gastroenterology 122A 2002 T833
54. Daniel F., Cadranel J.F., Seksik P., Marteau P. Azathioprine induced nodular regenerative hyperplasia in IBD patients Am J Gastroenterol 2004 (in press).
55. W.R. Connell, M.A. Kamm, M. Dickson, A.M. Balkwill, J.K. Ritchie, J.E. Lennard-Jones Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease Lancet 343 1994 1249 1952
56. J.D. Lewis, J.S. Schwartz, G.R. Lichtenstein Azathioprine for maintenance of remission in Crohn's disease benefits outweigh the risk of lymphoma Gastroenterology 118 2000 1018 1024
57. J.D. Lewis, W.B. Bilker, C. Brensinger, J.J. Deren, D.J. Vaughn, B.L. Strom Inflammatory bowel disease is not associated with an increased risk of lymphoma Gastroenterology 121 2001 1080 1087
58. C.H. Bernstein, J.F. Blanchard, E. Kliewer, A. Wajda Cancer risk in patients with inflammatory bowel disease a population based study Cancer 91 2001 854 862
59. E.V. Loftus, W.J. Tremaine, T.M. Habermann, W.S. Harmsen, A.R. Zinsmeitser, W.J. Sandborn Risk of lymphoma in inflammatory bowel disease Am J Gastroenterol 95 2000 2308 2312
60. G.A. Dayharsh, E.V. Loftus Jr, W.J. Sandborn, W.J. Tremaine, A.R. Zinsmeister, T.E. Witzig, W.R. Macon, L.J. Burgart Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine Gastroenterology 122 2002 72 77
61. B. Norgard, L. Pedersen, K. Fonager, S.N. Rasmussen, H.T. Sorensen Azathioprine, mercaptopurine and birth outcome a population-based cohort study Aliment Pharmacol Ther 17 2003 827 834
62. Zlatanic J., Korelitz B.I., Rajapakse R., Kim P.S., Rubin S.D., Baiocco P.J., Panagopoulos G. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease J Clin Gastroenterol 36 2003 303 309
63. A. Francella, A. Dyan, C. Bodian, P. Rubin, M. Chapman, D.H. Present The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease a retrospective cohort study Gastroenterology 124 2003 9 17
64. L. Lennard, C.A. Rees, J.S. Lilleyman, J.L. Maddocks Childhood leukemia a relationship between intracellular 6-MP metabolites and neutropenia Br J Clin Pharmacol 16 1983 358 363
65. L. Lennard, B.ES. Gibson, T. Nicole, J.S. Lilleyman Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukemia Arch Dis Child 69 1993 577 579
66. J.F. Colombel, N. Ferrari, H. Debuysere, P. Marteau, J.P. Gendre, B. Bonaz, J.C. Soule, R. Modigliani, Y. Touze, P. Catala, C. Libersa, F. Broly Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
67. A.J. Black, H.L. McLeod, H.A. Capell, R.H. Powrie, L.K. Matowe, S.C. Pritchard, E.S. Collie-Duguid, D.M. Reid Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 129 1998 716 718
68. L. Sebbag, P. Boucher, P. Davelu, P. Boissonnat, G. Champsaur, J. Ninet, G. Dureau, J.F. Obadia, J.J. Vallon, J. Delaye Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients Transplantation 69 2000 1524 1527
69. M. Regueiro, H. Mardini Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease J Clin Gastroenterol 35 2002 240 244
70. S. Campbell, K. Kingstone, S. Ghosh Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine Aliment Pharmacol Ther 16 2002 389 398
71. M. Seddik, F. Texier, N. Ferrari, A. Cortot, C. Libersa, F. Broly, J.F. Colombel Thiopurine methyltransferase genotyping does not predict azathioprine induced myelosuppression in Crohn's disease Gastroenterology 124 2003 A192
72. W. Curvers, L. Derijks, P. Stokkers, E. Vogels, J. De Gast, I. Pronk, A. Van Kampen, S. Van deventer, D. Hommes No predictive value of TPMT genotyping for leucopenia or hepatotoxicity during azathioprine therapy in inflammatory bowel disease Gastroenterology 124 2003 A49
73. A. Ansari, C. Hassan, J. Duley, A. Marinaki, E.-M. Shobowale-Bakre, P. Seed, J. Meenan, A. Yim, J. Sanderson Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease Aliment Pharmacol Ther 16 2002 1743 1750
74. C. Cuffari, T. Dassopoulos, L. Turnbough, R.E. Thompson, T.M. Bayless Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease Clin Gastroenterol Hepatol 2 2004 410 417
75. C. Cuffari, Y. Théorêt, S. Latour, E.G. Seidman 6-mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity Gut 39 1996 401 406
76. C. Cuffari, S. Hunt, T. Bayless Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease Gut 48 2001 642 646
77. P. Gupta, R. Gokhale, B. Kirschner 6-Mercaptopurine levels in children with inflammatory bowel disease J Pediatr Gastroenterol Nutr 33 2001 450 454
78. H.E. Mardini, G.L. Arnold Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting J Clin Gastroenterol 36 2003 390 395
79. P.W. Lowry, C.L. Franklin, A.L. Weaver, M.G. Pike, D.C. Mays, W.J. Tremaine, J.J. Lipsky, W.J. Sandborn Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease Gut 49 2001 665 670
80. J. Belaiche, J.P. Desager, Y. Horsmans, E. Louis Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease Scand J Gastroenterol 36 2001 71 76